Wadie B¹, Taha D¹, ElHefnawy A¹, Gaballah M¹

1. Urology and Nephrology Center

COMBINED MUS AND ANTERIOR COLPORRHAPHY VS. MUS ALONE IN THE TREATMENT OF SUI, RANDOMIZED CONTROLLED TRIAL

Hypothesis / aims of study

Midurethral sling (MUS) is the standard of care for female Stress urinary incontinence (SUI). Anecdotal experience suggested it can also correct low grade anterior Pelvic Organ Prolapse (POP). This study aims at comparing MUS alone vs. MUS and standard anterior colporrhaphy (AC) as a treatment of SUI concomitant with low grade anterior POP

Study design, materials and methods

This is a prospective randomized trialThis is an RCT carried out between November 2013 and March 2015. 75 patients had low grade anterior POP associated with SUI were enrolled. Patients were divided into 2 groups: Group 1 with MUS alone and group 2 with combined MUS and AC, 30 women each. Both groups were evaluated at 6 months

Results

Patients' demographics were shown in table I. At 6- month, anatomical cure rates were 31/39 (81.6%) and 26/36 (81.3%) in groups I and II respectively. One case from group 2 developed tape extrusion after 3 months and was managed by excision. Two anatomical failures were noted and both belong to group 2 and had TOT; were managed by redo colporrhaphy. Table 2 shows outcome at 6-month

Interpretation of results

		MUS	MUS & AC	P Value
		(n = 39)	(n = 36)	
Age		48.29 ± (8.22)	46.47 ± (7.901)	0.74
BMI		31.18 ± (6.91)	31.57 ± (4.43)	0.072
Parity		3.24 ± (1.30)	3.41 ± (1.15)	0.750
MUS type	TVT	15 (38.5%)	18(44.496)	0.390
	тот	11 (28.2%)	13 (38.1%)	
	PVS	13 (33.3%)	7 (19.4%)	

Table 2

ALPP	87.15 ± (31.17)	77.53 ± (30.32)	0.730
	25.90± (5.57)	24.70 ± (2.38)	0.984
Grade I	27 (71.1%)	9 (25.0%)	×
Grade II	11 (28.9%)	27 (75.0%)	NA
No POP	30 (77.0%)	27 (79.3%)	0.714
stage I	8 (20.5%)	6 (17.6%)	
stage II	1 (2.6%)	1 (2.9%)	
test	2.18 ± (4.26)	4.39 ± (1.83)	0.225
No POP	31 (81.6%)	26 (81.3%)	0.251
stage I	7 (18.4%)	4 (12.5%)	
	Grade II Ro POP stage II stage II test No POP	25.90± (5.57) Grade I 27 (71.196) Grade II 11 (28.996) No POP 30 (77.096) stage I 8 (20.5%) stage II 1 (2.6%) test 2.18± (4.26) No POP 31 (81.6%)	25.90± (5.57) 24.70± (2.38) Grade I 27 (71.1%) 9 (25.0%) Grade II 11 (28.9%) 27 (75.0%) No POP 30 (77.0%) 27 (79.3%) stage I 8 (20.5%) 6 (17.6%) stage II 1 (2.6%) 1 (2.9%) test 2.18± (4.26) 4.39± (1.83) No POP 31 (81.6%) 28 (81.3%)

Concluding message

In terms of anatomical cure rates, MUS alone was a successful treatment option when compared to combined MUS and AC at short -term.

Disclosures

Funding: Institutional Clinical Trial: Yes Public Registry: No RCT: Yes Subjects: HUMAN Ethics Committee: Urology Dept committee Helsinki: Yes Informed Consent: Yes